MicroRNAs as biomarkers for diagnosis, Prognosis and theranostics in prostate cancer

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Bertoli, Gloria ^a   Cava, Claudia ^a   Castiglioni, Isabella ^a  

^a CNR   (Italy)

Author keywords

Biomarkers; Diagnosis; microRNAs; Prognosis; Prostate cancer; Theranostics; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 148A; MICRORNA 16; MICRORNA 187; MICRORNA 197; MICRORNA 199A 3P; MICRORNA 20; MICRORNA 200C; MICRORNA 21; MICRORNA 221; MICRORNA 224; MICRORNA 233; MICRORNA 30C; MICRORNA 328; MICRORNA 34B; MICRORNA 375; MICRORNA 636; MICRORNA 640; MICRORNA 766; MICRORNA 855 5P; MICRORNA 92A; MICRORNA 99A; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR MARKER;

CANCER PROGNOSIS; DOWN REGULATION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THERANOSTIC NANOMEDICINE; UPREGULATION; ANIMAL; BLOOD; GENETICS; MALE; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS; RNAI THERAPEUTICS;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RNAI THERAPEUTICS;

EID: 84979053782     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030421     Document Type: Review

References (103)

1. Johnson, L. M.; Choyke, P. L.; Figg, W. D.; Turkbey, B. The role of MRI in prostate cancer active surveillance. BioMed Res. Int. 2014, 2014. [CrossRef] [PubMed]
2. Xu, W.; Zhou, M. A concise update on prostate pathology. Ceskoslov. Patol. 2014, 50, 120-128.
3. Humphrey, P. A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod. Pathol. 2004, 17, 292-306. [CrossRef] [PubMed]
4. Turkbey, B.; Brown, A. M.; Sankineni, S.; Wood, B. J.; Pinto, P. A.; Choyke, P. L. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J. Clin. 2015. [CrossRef] [PubMed]
5. Vickers, J.; Thompson, A.; Collins, G. S.; Childs, M.; Hain, R. Place and provision of palliative care for children with progressive cancer: A study by the Paediatric Oncology Nurses' Forum/United Kingdom Children's Cancer Study Group Palliative Care Working Group. J. Clin. Oncol. 2007, 25, 4472-4476. [CrossRef] [PubMed]
6. Carter, H. B.; Partin, A. W.; Walsh, P. C.; Trock, B. J.; Veltri, R. W.; Nelson, W. G.; Coffey, D. S.; Singer, E. A.; Epstein, J. I. Gleason score 6 adenocarcinoma: Should it be labeled as cancer? J. Clin. Oncol. 2012, 30, 4294-4296. [CrossRef] [PubMed]
7. Loeb, S.; Montorsi, F.; Catto, J. W. Future-proofing gleason grading: What to call gleason 6 prostate cancer? Eur. Urol. 2015, 68, 1-2. [CrossRef] [PubMed]
8. Pierorazio, P. M.; Walsh, P. C.; Partin, A. W.; Epstein, J. I. Prognostic gleason grade grouping: Data based on the modified gleason scoring system. BJU Int. 2013, 111, 753-760. [CrossRef] [PubMed]
9. Moore, C. M.; Emberton, M. Will the attributes of multiparametric MRI permit the creation of a new approach to therapy? Curr. Opin. Urol. 2015, 25, 518-521. [CrossRef] [PubMed]
10. Ozen, M.; Creighton, C. J.; Ozdemir, M.; Ittmann, M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27, 1788-1793. [CrossRef] [PubMed]
11. Porkka, K. P.; Pfeiffer, M. J.; Waltering, K. K.; Vessella, R. L.; Tammela, T. L.; Visakorpi, T. microRNA expression profiling in prostate cancer. Cancer Res. 2007, 67, 6130-6135. [CrossRef] [PubMed]
12. Rane, J. K.; Simms, M. S.; Maitland, N. J. Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome. Eur urol 2014; 65: 360-6: Telomerase expression and stem cells: Urologic epithelial perspective. Eur. Urol. 2014, 65, e85-e86. [PubMed]
13. Ren, Q.; Liang, J.; Wei, J.; Basturk, O.; Wang, J.; Daniels, G.; Gellert, L. L.; Li, Y.; Shen, Y.; Osman, I.; et al. Epithelial and stromal expression of miRNAs during prostate cancer progression. Am. J. Transl. Res. 2014, 6, 329-339. [PubMed]
14. Lin, S.; Gregory, R. I. microRNA biogenesis pathways in cancer. Nat. Rev. Cancer 2015, 15, 321-333. [CrossRef] [PubMed]
15. Bertoli, G.; Cava, C.; Castiglioni, I. microRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 2015, 5, 1122-1143. [CrossRef] [PubMed]
16. Ambs, S.; Prueitt, R. L.; Yi, M.; Hudson, R. S.; Howe, T. M.; Petrocca, F.; Wallace, T. A.; Liu, C. G.; Volinia, S.; Calin, G. A.; et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68, 6162-6170. [CrossRef] [PubMed]
17. Belair, C. D.; Paikari, A.; Moltzahn, F.; Shenoy, A.; Yau, C.; Dall'Era, M.; Simko, J.; Benz, C.; Blelloch, R. DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 2015, 16, 1219-1232. [CrossRef] [PubMed]
18. Chiosea, S.; Jelezcova, E.; Chandran, U.; Acquafondata, M.; McHale, T.; Sobol, R. W.; Dhir, R. Up-regulation of dicer, a component of the microRNA machinery, in prostate adenocarcinoma. Am. J. Pathol. 2006, 169, 1812-1820. [CrossRef] [PubMed]
19. Hessvik, N. P.; Sandvig, K.; Llorente, A. Exosomal miRNAs as biomarkers for prostate cancer. Front. Genet. 2013, 4. [CrossRef] [PubMed]
20. Javidi, M. A.; Ahmadi, A. H.; Bakhshinejad, B.; Nouraee, N.; Babashah, S.; Sadeghizadeh, M. Cell-freemicroRNAs as cancer biomarkers: The odyssey of miRNAs through body fluids. Med. Oncol. 2014, 31. [CrossRef] [PubMed]
21. Pigati, L.; Yaddanapudi, S. C.; Iyengar, R.; Kim, D. J.; Hearn, S. A.; Danforth, D.; Hastings, M. L.; Duelli, D. M. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE 2010, 5, e13515. [CrossRef] [PubMed]
22. Sita-Lumsden, A.; Dart, D. A.; Waxman, J.; Bevan, C. L. Circulating microRNAs as potential new biomarkers for prostate cancer. Br. J. Cancer 2013, 108, 1925-1930. [CrossRef] [PubMed]
23. Fong, M. Y.; Zhou, W.; Liu, L.; Alontaga, A. Y.; Chandra, M.; Ashby, J.; Chow, A.; O'Connor, S. T.; Li, S.; Chin, A. R.; et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 2015, 17, 183-194. [CrossRef] [PubMed]
24. Le, M. T.; Hamar, P.; Guo, C.; Basar, E.; Perdigao-Henriques, R.; Balaj, L.; Lieberman, J. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J. Clin. Investig. 2014, 124, 5109-5128. [CrossRef] [PubMed]
25. Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Hagiwara, K.; Takeshita, F.; Ochiya, T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J. Biol. Chem. 2012, 287, 1397-1405. [CrossRef] [PubMed]
26. Roa, W.; Brunet, B.; Guo, L.; Amanie, J.; Fairchild, A.; Gabos, Z.; Nijjar, T.; Scrimger, R.; Yee, D.; Xing, J. Identification of a new microRNA expression profile as a potential cancer screening tool. Clin. Investig. Med. Med. Clin. Exp. 2010, 33, E124-E132.
27. Selth, L. A.; Roberts, M. J.; Chow, C. W.; Marshall, V. R.; Doi, S. A.; Vincent, A. D.; Butler, L. M.; Lavin, M. F.; Tilley, W. D.; Gardiner, R. A. Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocr. Relat. Cancer 2014, 21, L17-L21. [CrossRef] [PubMed]
28. Szczyrba, J.; Loprich, E.; Wach, S.; Jung, V.; Unteregger, G.; Barth, S.; Grobholz, R.; Wieland, W.; Stohr, R.; Hartmann, A.; et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol. Cancer Res. 2010, 8, 529-538. [CrossRef] [PubMed]
29. Schaefer, A.; Jung, M.; Mollenkopf, H. J.; Wagner, I.; Stephan, C.; Jentzmik, F.; Miller, K.; Lein, M.; Kristiansen, G.; Jung, K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126, 1166-1176. [CrossRef] [PubMed]
30. Wach, S.; Nolte, E.; Szczyrba, J.; Stohr, R.; Hartmann, A.; Orntoft, T.; Dyrskjot, L.; Eltze, E.; Wieland, W.; Keck, B.; et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int. J. Cancer 2012, 130, 611-621. [CrossRef] [PubMed]
31. Liu, D. F.; Wu, J. T.; Wang, J. M.; Liu, Q. Z.; Gao, Z. L.; Liu, Y. X. MicroRNA expression profile analysis reveals diagnostic biomarker for human prostate cancer. Asian Pac. J. Cancer Prev. 2012, 13, 3313-3317. [CrossRef] [PubMed]
32. Kelly, B. D.; Miller, N.; Sweeney, K. J.; Durkan, G. C.; Rogers, E.; Walsh, K.; Kerin, M. J. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J. Clin. Med. 2015, 4, 1369-1379. [CrossRef] [PubMed]
33. Casanova-Salas, I.; Rubio-Briones, J.; Calatrava, A.; Mancarella, C.; Masia, E.; Casanova, J.; Fernandez-Serra, A.; Rubio, L.; Ramirez-Backhaus, M.; Arminan, A.; et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J. Urol. 2014, 192, 252-259. [CrossRef] [PubMed]
34. Catto, J. W.; Shariat, S. F. The changing face of renal cell carcinoma: The impact of systematic genetic sequencing on our understanding of this tumor1s biology. Eur. Urol. 2013, 63, 855-857. [CrossRef] [PubMed]
35. Coppola, V.; de Maria, R.; Bonci, D. MicroRNAs and prostate cancer. Endocr. Relat. Cancer 2010, 17, F1-F17. [CrossRef] [PubMed]
36. Hessvik, N. P.; Phuyal, S.; Brech, A.; Sandvig, K.; Llorente, A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim. Biophys. Acta 2012, 1819, 1154-1163. [CrossRef] [PubMed]
37. Mitchell, P. S.; Parkin, R. K.; Kroh, E. M.; Fritz, B. R.; Wyman, S. K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; O'Briant, K. C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518. [CrossRef] [PubMed]
38. Selth, L. A.; Townley, S.; Gillis, J. L.; Ochnik, A. M.; Murti, K.; Macfarlane, R. J.; Chi, K. N.; Marshall, V. R.; Tilley, W. D.; Butler, L. M. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int. J. Cancer 2012, 131, 652-661. [CrossRef] [PubMed]
39. Lodes, M. J.; Caraballo, M.; Suciu, D.; Munro, S.; Kumar, A.; Anderson, B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009, 4, e6229. [CrossRef] [PubMed]
40. Moltzahn, F.; Olshen, A. B.; Baehner, L.; Peek, A.; Fong, L.; Stoppler, H.; Simko, J.; Hilton, J. F.; Carroll, P.; Blelloch, R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011, 71, 550-560. [CrossRef] [PubMed]
41. Yaman Agaoglu, F.; Kovancilar, M.; Dizdar, Y.; Darendeliler, E.; Holdenrieder, S.; Dalay, N.; Gezer, U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011, 32, 583-588. [CrossRef] [PubMed]
42. Brase, J. C.; Johannes, M.; Schlomm, T.; Falth, M.; Haese, A.; Steuber, T.; Beissbarth, T.; Kuner, R.; Sultmann, H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128, 608-616. [CrossRef] [PubMed]
43. Mahn, R.; Heukamp, L. C.; Rogenhofer, S.; von Ruecker, A.; Muller, S. C.; Ellinger, J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011, 77, e1269-e1216. [CrossRef] [PubMed]
44. Bryant, R. J.; Pawlowski, T.; Catto, J. W.; Marsden, G.; Vessella, R. L.; Rhees, B.; Kuslich, C.; Visakorpi, T.; Hamdy, F. C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106, 768-774. [CrossRef] [PubMed]
45. Haldrup, C.; Kosaka, N.; Ochiya, T.; Borre, M.; Hoyer, S.; Orntoft, T. F.; Sorensen, K. D. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv. Transl. Res. 2014, 4, 19-30. [CrossRef] [PubMed]
46. Chen, Z. H.; Zhang, G. L.; Li, H. R.; Luo, J. D.; Li, Z. X.; Chen, G. M.; Yang, J. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012, 72, 1443-1452. [CrossRef] [PubMed]
47. Medina-Villaamil, V.; Martinez-Breijo, S.; Portela-Pereira, P.; Quindos-Varela, M.; Santamarina-Cainzos, I.; Anton-Aparicio, L. M.; Gomez-Veiga, F. Circulating microRNAs in blood of patients with prostate cancer. Actas Urol. Esp. 2014, 38, 633-639. [CrossRef] [PubMed]
48. Kachakova, D.; Mitkova, A.; Popov, E.; Popov, I.; Vlahova, A.; Dikov, T.; Christova, S.; Mitev, V.; Slavov, C.; Kaneva, R. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol. 2015, 34, 189-200. [CrossRef] [PubMed]
49. Ahumada-Tamayo, S.; Saavedra-Briones, D.; Cantellano-Orozco, M.; Salido-Guadarrama, A.; Rodríguez-Dorantes, M.; Urdiales-Ortiz, A.; Hernández-Castellanos, V.; Merayo-Chalico, C.; Sánchez-Turati, G.; Santana-Ríos, Z.; et al. MicroRNA determination in urine for prostate cancer detection in Mexican patients at the hospital general "Dr. Manuelgea gonzález". Rev. Mex. Urol. 2011, 71, 213-217.
50. Egidi, M. G.; Cochetti, G.; Serva, M. R.; Guelfi, G.; Zampini, D.; Mechelli, L.; Mearini, E. Circulating microRNAs and kallikreins before and after radical prostatectomy: Are they really prostate cancer markers? BioMed Res. Int. 2013, 2013. [CrossRef] [PubMed]
51. Sachdeva, M.; Zhu, S.; Wu, F.; Wu, H.; Walia, V.; Kumar, S.; Elble, R.; Watabe, K.; Mo, Y. Y. P53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA 2009, 106, 3207-3212. [CrossRef] [PubMed]
52. Wagner, S.; Ngezahayo, A.; Murua Escobar, H.; Nolte, I. Role of miRNA let-7 and its major targets in prostate cancer. BioMed Res. Int. 2014, 2014. [CrossRef] [PubMed]
53. Musumeci, M.; Coppola, V.; Addario, A.; Patrizii, M.; Maugeri-Sacca, M.; Memeo, L.; Colarossi, C.; Francescangeli, F.; Biffoni, M.; Collura, D.; et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011, 30, 4231-4242. [CrossRef] [PubMed]
54. Yang, X.; Du, W. W.; Li, H.; Liu, F.; Khorshidi, A.; Rutnam, Z. J.; Yang, B. B. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res. 2013, 41, 9688-9704. [CrossRef] [PubMed]
55. Park, J. K.; Lee, E. J.; Esau, C.; Schmittgen, T. D. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009, 38, e190-e199. [CrossRef] [PubMed]
56. Xu, L.; Dai, W. Q.; Xu, X. F.; Wang, F.; He, L.; Guo, C. Y. Effects of multiple-target anti-microRNA antisense oligodeoxyribonucleotides on proliferation and migration of gastric cancer cells. Asian Pac. J. Cancer Prev. 2012, 13, 3203-3207. [CrossRef] [PubMed]
57. Zoni, E.; van der Horst, G.; van de Merbel, A. F.; Chen, L.; Rane, J. K.; Pelger, R. C.; Collins, A. T.; Visakorpi, T.; Snaar-Jagalska, B. E.; Maitland, N. J.; et al. miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv-and α6-integrin expression. Cancer Res. 2015, 75, 2326-2336. [CrossRef] [PubMed]
58. Tong, A. W.; Fulgham, P.; Jay, C.; Chen, P.; Khalil, I.; Liu, S.; Senzer, N.; Eklund, A. C.; Han, J.; Nemunaitis, J. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009, 16, 206-216. [CrossRef] [PubMed]
59. Volinia, S.; Calin, G. A.; Liu, C. G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257-2261. [CrossRef] [PubMed]
60. Leite, K. R.; Tomiyama, A.; Reis, S. T.; Sousa-Canavez, J. M.; Sanudo, A.; Dall'Oglio, M. F.; Camara-Lopes, L. H.; Srougi, M. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J. Urol. 2011, 185, 1118-1122. [CrossRef] [PubMed]
61. Martens-Uzunova, E. S.; Jalava, S. E.; Dits, N. F.; van Leenders, G. J.; Moller, S.; Trapman, J.; Bangma, C. H.; Litman, T.; Visakorpi, T.; Jenster, G. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012, 31, 978-991. [CrossRef] [PubMed]
62. Tsuchiyama, K.; Ito, H.; Taga, M.; Naganuma, S.; Oshinoya, Y.; Nagano, K.; Yokoyama, O.; Itoh, H. Expression of microRNAs associated with gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. Prostate 2013, 73, 827-834. [CrossRef] [PubMed]
63. Lichner, Z.; Fendler, A.; Saleh, C.; Nasser, A. N.; Boles, D.; Al-Haddad, S.; Kupchak, P.; Dharsee, M.; Nuin, P. S.; Evans, K. R.; et al. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin. Chem. 2013, 59, 1595-1603. [CrossRef] [PubMed]
64. Schubert, M.; Spahn, M.; Kneitz, S.; Scholz, C. J.; Joniau, S.; Stroebel, P.; Riedmiller, H.; Kneitz, B. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS ONE 2013, 8, e65064. [CrossRef] [PubMed]
65. Larne, O.; Martens-Uzunova, E.; Hagman, Z.; Edsjo, A.; Lippolis, G.; den Berg, M. S.; Bjartell, A.; Jenster, G.; Ceder, Y. miQ-A novel microRNA based diagnostic and prognostic tool for prostate cancer. Int. J. Cancer. 2013, 132, 2867-2875. [CrossRef] [PubMed]
66. Haflidadottir, B. S.; Larne, O.; Martin, M.; Persson, M.; Edsjo, A.; Bjartell, A.; Ceder, Y. Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS ONE 2013, 8, e72400. [CrossRef] [PubMed]
67. Costa-Pinheiro, P.; Montezuma, D.; Henrique, R.; Jeronimo, C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics 2015, 7, 1003-1015. [CrossRef] [PubMed]
68. Wallis, C. J.; Gordanpour, A.; Bendavid, J. S.; Sugar, L.; Nam, R. K.; Seth, A. miR-182 is associated with growth, migration and invasion in prostate cancer via suppression of FOXO1. J. Cancer 2015, 6, 1295-1305. [CrossRef] [PubMed]
69. Huang, Z.; Zhang, L.; Yi, X.; Yu, X. Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma. Tumour Biol. 2015. [CrossRef] [PubMed]
70. Varambally, S.; Cao, Q.; Mani, R. S.; Shankar, S.; Wang, X.; Ateeq, B.; Laxman, B.; Cao, X.; Jing, X.; Ramnarayanan, K.; et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322, 1695-1699.
71. Cai, C.; Chen, Q. B.; Han, Z. D.; Zhang, Y. Q.; He, H. C.; Chen, J. H.; Chen, Y. R.; Yang, S. B.; Wu, Y. D.; Zeng, Y. R.; et al. miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin. Cancer Res. 2015, 21, 4922-4934. [CrossRef] [PubMed]
72. Dezhong, L.; Xiaoyi, Z.; Xianlian, L.; Hongyan, Z.; Guohua, Z.; Bo, S.; Shenglei, Z.; Lian, Z. miR-150 is a factor of survival in prostate cancer patients. J. BUON 2015, 20, 173-179. [PubMed]
73. Zhang, H.; Qi, S.; Zhang, T.; Wang, A.; Liu, R.; Guo, J.; Wang, Y.; Xu, Y. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget 2015, 6, 6092-6104. [CrossRef] [PubMed]
74. Nam, R. K.; Amemiya, Y.; Benatar, T.; Wallis, C. J.; Stojcic-Bendavid, J.; Bacopulos, S.; Sherman, C.; Sugar, L.; Naeim, M.; Yang, W.; et al. Identification and validation of a five microRNA signature predictive of prostate cancer recurrence and metastasis: A cohort study. J. Cancer 2015, 6, 1160-1171. [CrossRef] [PubMed]
75. Westermann, A. M.; Schmidt, D.; Holdenrieder, S.; Moritz, R.; Semjonow, A.; Schmidt, M.; Kristiansen, G.; Muller, S. C.; Ellinger, J. Serum microRNAs as biomarkers in patients undergoing prostate biopsy: Results from a prospective multi-center study. Anticancer Res. 2014, 34, 665-669. [PubMed]
76. Shen, J.; Hruby, G. W.; McKiernan, J. M.; Gurvich, I.; Lipsky, M. J.; Benson, M. C.; Santella, R. M. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012, 72, 1469-1477. [CrossRef] [PubMed]
77. Liu, C.; Guan, H.; Wang, Y.; Chen, M.; Xu, B.; Zhang, L.; Lu, K.; Tao, T.; Zhang, X.; Huang, Y. miR-195 inhibits emt by targeting FGF2 in prostate cancer cells. PLoS ONE 2015, 10, e0144073. [CrossRef] [PubMed]
78. Zhang, H. L.; Qin, X. J.; Cao, D. L.; Zhu, Y.; Yao, X. D.; Zhang, S. L.; Dai, B.; Ye, D. W. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J. Androl. 2013, 15, 231-235. [CrossRef] [PubMed]
79. Wang, C.; Tao, W.; Ni, S.; Chen, Q.; Zhao, Z.; Ma, L.; Fu, Y.; Jiao, Z. Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci. 2015, 106, 375-382. [CrossRef] [PubMed]
80. Mierswa, I.; Wurst, M.; Klinkenberg, R.; Scholz, M.; Euler, T. Yale: Rapid prototyping for complex data mining tasks. In Proceedings of the 12th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, Philadelphia, PA, USA, 20-23 August 2006; pp. 935-940.
81. Colaprico, A.; Silva, T. C.; Olsen, C.; Garofano, L.; Cava, C.; Garolini, D.; Sabedot, T. S.; Malta, T. M.; Pagnotta, S. M.; Castiglioni, I.; et al. TCGabiolinks: An R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015. [CrossRef] [PubMed]
82. Moldovan, L.; Batte, K. E.; Trgovcich, J.; Wisler, J.; Marsh, C. B.; Piper, M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J. Cell. Mol. Med. 2014, 18, 371-390. [CrossRef] [PubMed]
83. Weber, J. A.; Baxter, D. H.; Zhang, S.; Huang, D. Y.; Huang, K. H.; Lee, M. J.; Galas, D. J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56, 1733-1741. [CrossRef] [PubMed]
84. Hawley, S.; Fazli, L.; McKenney, J. K.; Simko, J.; Troyer, D.; Nicolas, M.; Newcomb, L. F.; Cowan, J. E.; Crouch, L.; Ferrari, M.; et al. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: The canary prostate cancer tissue microarray. Adv. Anat. Pathol. 2013, 20, 39-44. [CrossRef] [PubMed]
85. Qu, Y.; Huang, X.; Li, Z.; Liu, J.; Wu, J.; Chen, D.; Zhao, F.; Mu, D. miR-199a-3p inhibits aurora kinase a and attenuates prostate cancer growth: New avenue for prostate cancer treatment. Am. J. Pathol. 2014, 184, 1541-1549. [CrossRef] [PubMed]
86. Bonci, D.; Coppola, V.; Patrizii, M.; Addario, A.; Cannistraci, A.; Francescangeli, F.; Pecci, R.; Muto, G.; Collura, D.; Bedini, R.; et al. A microRNA code for prostate cancer metastasis. Oncogene 2016, 35, 1180-1192. [CrossRef] [PubMed]
87. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R. U.; Yamamoto, Y.; Kosaka, N.; Kawamata, M.; Kelnar, K.; Bader, A. G.; Brown, D.; et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18, 181-187. [CrossRef] [PubMed]
88. Gong, P.; Zhang, T.; He, D.; Hsieh, J. T. MicroRNA-145 modulates tumor sensitivity to radiation in prostate cancer. Radiat. Res. 2015, 184, 630-638. [CrossRef] [PubMed]
89. Yan, J. W.; Lin, J. S.; He, X. X. The emerging role of miR-375 in cancer. Int. J. Cancer. 2014, 135, 1011-1018. [CrossRef] [PubMed]
90. Chang, Y.; Yan, W.; He, X.; Zhang, L.; Li, C.; Huang, H.; Nace, G.; Geller, D. A.; Lin, J.; Tsung, A. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012, 143, 177-187. [CrossRef] [PubMed]
91. Ding, L.; Xu, Y.; Zhang, W.; Deng, Y.; Si, M.; Du, Y.; Yao, H.; Liu, X.; Ke, Y.; Si, J.; et al. miR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010, 20, 784-793. [CrossRef] [PubMed]
92. Kong, K. L.; Kwong, D. L.; Chan, T. H.; Law, S. Y.; Chen, L.; Li, Y.; Qin, Y. R.; Guan, X. Y. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61, 33-42. [CrossRef] [PubMed]
93. Friedman, R. C.; Farh, K. K.; Burge, C. B.; Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92-105. [CrossRef] [PubMed]
94. Dong, Q.; Meng, P.; Wang, T.; Qin, W.; Qin, W.; Wang, F.; Yuan, J.; Chen, Z.; Yang, A.; Wang, H. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2f2 and CCND2. PLoS ONE 2010, 5, e10147. [CrossRef] [PubMed]
95. Williams, L. V.; Veliceasa, D.; Vinokour, E.; Volpert, O. V. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS ONE 2013, 8, e83991. [CrossRef] [PubMed]
96. Mercatelli, N.; Coppola, V.; Bonci, D.; Miele, F.; Costantini, A.; Guadagnoli, M.; Bonanno, E.; Muto, G.; Frajese, G. V.; De Maria, R.; et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 2008, 3, e4029. [CrossRef] [PubMed]
97. Bader, A. G. miR-34-A microRNA replacement therapy is headed to the clinic. Front. Genet. 2012, 3. [CrossRef] [PubMed]
98. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.; Jeter, C.; Honorio, S.; et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17, 211-215. [CrossRef] [PubMed]
99. Fujita, Y.; Kojima, K.; Hamada, N.; Ohhashi, R.; Akao, Y.; Nozawa, Y.; Deguchi, T.; Ito, M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2008, 377, 114-119. [CrossRef] [PubMed]
100. Kojima, K.; Fujita, Y.; Nozawa, Y.; Deguchi, T.; Ito, M. miR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010, 70, 1501-1512. [CrossRef] [PubMed]
101. Sanchez, C. A.; Andahur, E. I.; Valenzuela, R.; Castellon, E. A.; Fulla, J. A.; Ramos, C. G.; Trivino, J. C. Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget 2016, 26, 3993-4008.
102. Misso, G.; di Martino, M. T.; de Rosa, G.; Farooqi, A. A.; Lombardi, A.; Campani, V.; Zarone, M. R.; Gulla, A.; Tagliaferri, P.; Tassone, P.; et al. miR-34: A new weapon against cancer? Mol. Ther. Nucleic Acids 2014, 3. [CrossRef] [PubMed]
103. Mirna Therapeutics, Inc. microRNA Replacement Therapy. Available online: http: //www. mirnarx. com/ pipeline/mirna-MRX34. html (accessed on 30 October 2015).